磁共振引导前列腺、盆腔及转移灶同步多靶区自适应放疗的前瞻性II期研究
该前瞻性单臂II期研究纳入35例高危、极高危或寡转移性前列腺癌患者,采用1.5-T MR-Linac实施MRgSMART-PEM,隔日5次、Adapt-to-Shape流程。主要终点为12周内急性≥2级泌尿生殖和胃肠道毒性,结果为各5.7%,未见晚期≥2级毒性;2年生化与临床无进展生存率均为87.4%,野内控制率100%。
要点
- 急性≥2级GU与GI毒性各为5.7%,含1例3级GI事件且8周内均缓解
- 中位随访17.2个月未见晚期≥2级毒性,生活质量3个月恢复至基线
- 2年生化与临床无进展生存率均为87.4%,野内控制率100%
核心结论
- MRgSMART-PEM在高危、极高危及寡转移性前列腺癌患者中可行、安全且耐受良好,局部控制优异、毒性轻微且生活质量恢复,支持进一步开展随机试验验证。
研究设计与样本
- 前瞻性单臂II期研究,纳入35例病理确诊前列腺癌患者(11例局限、8例盆腔淋巴结、16例寡转移)。
- 2021年6月至2025年3月在1.5-T MR-Linac上实施MRgSMART-PEM,隔日5次、Adapt-to-Shape工作流程。
- 主要终点为12周内临床医生报告的急性≥2级泌尿生殖(GU)和胃肠道(GI)毒性;次要终点包括晚期毒性、生活质量与生存结局。
- 试验注册号NCT05183074(中国医学科学院,2022-01-10首次发布)。
主要发现
- 中位随访17.2个月(范围4.3–49.3),中位治疗床时间59分钟(范围35–80)。
- 急性≥2级GU和GI毒性均见于5.7%的患者,含1例3级GI事件,均在8周内缓解。
- 未观察到晚期≥2级毒性,无1级事件持续超过18个月。
- 生活质量评分在治疗后2周下降,3个月恢复至基线。
- 2年时生化与临床无进展生存率均为87.4%,野内控制率为100%。
关键数值与推荐
- 主要终点:12周内急性≥2级GU毒性5.7%、GI毒性5.7%(35例患者中)。
- 晚期毒性:无≥2级事件,无1级事件持续超过18个月。
- 2年生化与临床无进展生存率均为87.4%,野内控制率100%。
- 生活质量:治疗后2周下降,3个月恢复至基线。
临床怎么用
- 该方案在1.5-T MR-Linac上隔日5次实施,中位床旁时间59分钟,可作为高危及寡转移前列腺癌同步多靶区放疗的可行选择。
- 治疗期间需关注急性GU与GI毒性,本研究显示多可于8周内缓解,但需警惕偶发3级GI事件。
- 治疗前2周生活质量可能下降,应向患者说明3个月内多可恢复至基线。
- 2年野内控制率100%提示局部控制良好,但仍需随机试验进一步验证。
- 研究未报告具体剂量分割参数,临床实施需结合本机构流程确定。
局限性
- 单臂设计、样本量35例,缺乏对照组,结论需随机试验验证。
- 中位随访仅17.2个月,晚期毒性与生存数据尚不成熟。
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety, feasibility, and patient-reported outcomes of magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for the prostate, pelvis, and metastases (MRgSMART-PEM) in patients with high-risk, very-high-risk, or oligometastatic prostate cancer. METHODS AND MATERIALS: In this prospective single-arm phase II study, 35 patients with pathologically confirmed prostate cancer (11 localized, 8 pelvic nodal, 16 oligometastatic) were treated with MRgSMART-PEM on a 1.5-T MR-Linac between June 2021 and March 2025. Radiotherapy was delivered in five alternate-day fractions using an Adapt-to-Shape workflow. The primary endpoint was clinician-reported acute grade ≥ 2 genitourinary (GU) and gastrointestinal (GI) toxicity within 12 weeks. Secondary endpoints included late toxicity, quality of life (QoL), and survival outcomes. RESULTS: Median follow-up was 17.2 months (range, 4.3–49.3). The median on-couch time was 59 min (range, 35–80). Acute grade ≥ 2 GU and GI toxicities occurred in 5.7% of patients each, including one grade 3 GI event; all resolved within 8 weeks. No late grade ≥ 2 toxicities were observed, and no grade 1 events persisted beyond 18 months. QoL scores declined at 2 weeks post-treatment but returned to baseline by 3 months. At 2 years, biochemical and clinical progression-free survival rates were both 87.4%, and in-field control was 100%. CONCLUSIONS: MRgSMART-PEM is feasible, safe, and well tolerated in patients with high-risk, very-high-risk, and oligometastatic prostate cancer, achieving excellent local control with minimal toxicity and recovery of QoL. These results support further evaluation of MRgSMART-PEM in randomized trials. TRIAL REGISTRATION: NCT05183074 (Chinese Academy of Medical Sciences, First Posted 2022-01-10).
引用
- Sun M, Qin SR, Wei R, et al. Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study. Radiat Oncol. 2026. PMID: 41689033. doi:10.1186/s13014-026-02799-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。